DKN-01单药或联合多西他赛治疗转移性去势抵抗性前列腺癌的1/2期多中心试验
这项研究者发起的平行组1/2期试验评估DKN-01单药或联合多西他赛75 mg/m2治疗转移性去势抵抗性前列腺癌(mCRPC)患者,这些患者在接受至少1种雄激素受体信号抑制剂后进展。共入组18例患者,未观察到剂量限制性毒性,确定DKN-01 600 mg为2期推荐剂量。单药组可评估患者中2/7(29%)达疾病稳定最佳总体缓解,联合组可评估患者中5/7(71%)达部分缓解,联合组中位影像学无进展生存期为5.7个月。
要点
- DKN-01 600 mg被确定为2期推荐剂量,未观察到剂量限制性毒性。
- 联合组可评估患者中5/7(71%)达部分缓解,中位rPFS为5.7个月。
- 联合组中DKK1 H-score≥1与H-score=0患者的rPFS相似。
核心结论
- DKN-01 600 mg耐受性良好;DKK1阻断作为mCRPC单药治疗具有中等抗肿瘤活性;联合组观察到抗肿瘤活性但缓解持续时间有限;多数mCRPC中DKK1表达低,且与DKN-01联合多西他赛的抗肿瘤活性无明确相关性。
研究设计与样本
- 研究者发起的平行组1/2期临床试验,评估DKN-01单药或联合多西他赛75 mg/m2治疗转移性去势抵抗性前列腺癌(mCRPC)患者,这些患者在接受至少1种雄激素受体信号抑制剂后进展。
- DKK1状态通过RNA原位表达确定;1期剂量递增队列主要终点为确定2期推荐剂量(RP2D),2期扩展队列主要终点为联合治疗患者的iRECIST客观缓解率。
- 共入组18例患者:单药队列10例,联合队列8例。
主要发现
- 未观察到剂量限制性毒性,DKN-01 600 mg被确定为RP2D。
- 单药队列可评估患者中2/7(29%)达疾病稳定最佳总体缓解。
- 联合队列可评估患者中5/7(71%)达部分缓解(PR)。
- 联合队列中位影像学无进展生存期(rPFS)为5.7个月。
- 联合队列中位肿瘤DKK1表达H-score为0.75;DKK1 H-score≥1与H-score=0患者的rPFS相似。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Dickkopf-related protein 1 (DKK1) is a Wingless-related integrate site (Wnt) signaling modulator that is upregulated in prostate cancers (PCa) with low androgen receptor expression. DKN-01, an IgG4 that neutralizes DKK1, delays PCa growth in pre-clinical DKK1-expressing models. These data provided the rationale for a clinical trial testing DKN-01 in patients with metastatic castration-resistant PCa (mCRPC). METHODS: This was an investigator-initiated parallel-arm phase 1/2 clinical trial testing DKN-01 alone (monotherapy) or in combination with docetaxel 75 mg/m2 (combination) for men with mCRPC who progressed on ≥1 AR signaling inhibitors. DKK1 status was determined by RNA in-situ expression. The primary endpoint of the phase 1 dose escalation cohorts was the determination of the recommended phase 2 dose (RP2D). The primary endpoint of the phase 2 expansion cohorts was objective response rate by iRECIST criteria in patients treated with the combination. RESULTS: 18 pts were enrolled into the study-10 patients in the monotherapy cohorts and 8 patients in the combination cohorts. No DLTs were observed and DKN-01 600 mg was determined as the RP2D. A best overall response of stable disease occurred in two out of seven (29%) evaluable patients in the monotherapy cohort. In the combination cohort, five out of seven (71%) evaluable patients had a partial response (PR). A median rPFS of 5.7 months was observed in the combination cohort. In the combination cohort, the median tumoral DKK1 expression H-score was 0.75 and the rPFS observed was similar between patients with DKK1 H-score ≥1 versus H-score = 0. CONCLUSION: DKN-01 600 mg was well tolerated. DKK1 blockade has modest anti-tumor activity as a monotherapy for mCRPC. Anti-tumor activity was observed in the combination cohorts, but the response duration was limited. DKK1 expression in the majority of mCRPC is low and did not clearly correlate with anti-tumor activity of DKN-01 plus docetaxel.
引用
- Wise DR, Pachynski RK, Denmeade SR, et al. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer Prostatic Dis. 2024. PMID: 38341461. doi:10.1038/s41391-024-00798-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。